Trademark: 88891086
Word
PINPOINT
Status
Pending
Status Code
733
Status Date
Monday, September 9, 2024
Serial Number
88891086
Mark Type
4
Filing Date
Tuesday, April 28, 2020
Published for Opposition
Tuesday, July 19, 2022

Trademark Owner History
Dragonfly Therapeutics, Inc. - Owner At Publication

Classifications
42 Services in the field of computer assisted research in the nature of pharmaceutical research in the field of research and development of therapeutic biomolecules, namely, bioinformatics services directed to immune-engaging therapeutic biomolecule research and development; Services using computer algorithms for analysis of bioinformatics data in the field of research and development of therapeutic biomolecules for the treatment of cancer, autoimmune disease, infectious disease, or other diseases, namely services to analyze immunotherapy treatments, including treatment of cancer, autoimmune disease, infectious disease, fibrotic disease, or cellular senescence; Services using computer algorithms for analysis of bioinformatics data in the field of research and development of therapeutic biomolecules for the treatment of cancer, autoimmune disease, infectious disease, or other diseases, namely, services using comparative analysis across diseased and healthy tissue, between patients, between cells, comparing protein expression and surface localization information, and analysis of preclinical and clinical data from therapeutic biomolecules, to identify targets for immunotherapy development; all of the foregoing excluding providing temporary use of non-downloadable computer software for data mining, data query, and data analysis excluding providing temporary use of non-downloadable computer software for applying statistical, econometric, and machine learning methods to data sets to generate data transformations and analyses and for displaying, visualizing, and interpreting the results of these data transformations and analyses; excluding providing temporary use of non-downloadable computer software, namely, educational software featuring instruction, testing, and assessment in the fields of statistics, econometrics, and machine learning for secondary, postsecondary and skills education; excluding biological preparations biological preparations in the nature of eukaryotic cells, isogenic cell lines and bio-production cell lines generated using base editing engineering for scientific, laboratory or medical research; excluding reagents, plasmids and assays for scientific, genetic and medical research; excluding genomic reference control samples for medical laboratory use; excluding molecular biology research tools, in the nature of chemical, biological and biochemical reagents; excluding biological preparations in the nature of separate base editing components including mRNA, rRNA, gRNA, deaminase, nickase, ribonucleotide protein (RNP) for use in scientific, laboratory or medical research; excluding biological preparations in the nature of genetically modified cells and vectors for scientific and research purposes; excluding biological and chemical reagents including complexes of these molecules for research and for clinical and industrial use; excluding diagnostic preparations and materials generated by the use of base editing components for medical purposes; excluding chemical preparation for use in DNA analysis for medical purposes; excluding biological preparations in the nature of DNA, RNA and parts thereof for medical purposes; excluding biological preparations in the nature of DNA extracts for medical purposes; excluding biological preparations in the nature of gene editing enzymes for medical purposes; excluding biological preparations in the nature of protein cell lysates, genomic DNA preparations and Formalin Fixed, Paraffin Embedded (FFPE) engineered tumour tissue mimics for medical diagnostic use; excluding biological preparations in the nature of biological, biochemical and chemical reagents, including living cells, genetically modified cells and vectors, genomic DNA, cell cultures and mutant and normal isogenic cell line pairs, peptides, proteins and nucleic acids or complexes of these molecules for medical use; excluding collections of DNA and gene sequences for research and reference purposes provided as DNA microarrays and DNA chips; excluding treatment of biopharmaceutical materials; excluding custom manufacture of cells and vectors for diagnostic, medical and commercial applications in relation to cell and gene therapies; excluding custom cell-line engineering services; excluding gene base-editing services for research purposes; excluding gene engineering services; excluding research and development services in the creation of databases or collections of information on biologicals including cells and cell lines for research purposes; excluding creating and providing databases or collections of information on normal and mutated genes for research purposes; excluding providing DNA reference standards for research purposes; excluding providing DNA reference databases being collections of DNA and gene sequences for research purposes; excluding research on cell line models; excluding contract research on cell line models; excluding research and development services relating to targeting therapies to individuals; excluding establishing patient genotypes for research or analysis purposes; excluding research and development services relating to combining therapies for individuals; excluding research and development relating to reagents; excluding disease modelling for research purposes; excluding design of clinical trials for research purposes; excluding research and development in re-positioning existing drugs from other therapeutic indications; excluding services relating to biological and medical research and research and development in the field of cells and cell therapies, genome editing, genetic engineering and gene therapies

Trademark Events
Aug 7, 2020
Non-Final Action Written
May 1, 2020
New Application Entered
May 8, 2020
New Application Office Supplied Data Entered
Jul 22, 2020
Assigned To Examiner
Feb 8, 2021
Correspondence Received In Law Office
Aug 7, 2020
Non-Final Action E-Mailed
Aug 7, 2020
Notification Of Non-Final Action E-Mailed
Feb 8, 2021
Teas Response To Office Action Received
Feb 9, 2021
Teas/Email Correspondence Entered
Apr 19, 2021
Suspension Letter Written
Apr 19, 2021
Letter Of Suspension E-Mailed
Apr 19, 2021
Notification Of Letter Of Suspension E-Mailed
Aug 23, 2021
Assigned To Examiner
Oct 27, 2021
Suspension Checked - To Attorney For Action
May 23, 2022
Teas Response To Office Action Received
Nov 23, 2021
Non-Final Action Written
Nov 23, 2021
Non-Final Action E-Mailed
Nov 23, 2021
Notification Of Non-Final Action E-Mailed
May 23, 2022
Correspondence Received In Law Office
May 27, 2022
Teas/Email Correspondence Entered
Jun 16, 2022
Approved For Pub - Principal Register
Jul 19, 2022
Official Gazette Publication Confirmation E-Mailed
Jun 29, 2022
Notification Of Notice Of Publication E-Mailed
Jul 19, 2022
Published For Opposition
Sep 13, 2022
Noa E-Mailed - Sou Required From Applicant
Feb 20, 2023
Sou Extension 1 Granted
Feb 20, 2023
Sou Teas Extension Received
Feb 20, 2023
Sou Extension 1 Filed
Mar 6, 2024
Sou Extension 3 Filed
Feb 22, 2023
Notice Of Approval Of Extension Request E-Mailed
Sep 11, 2023
Sou Teas Extension Received
Sep 11, 2023
Sou Extension 2 Filed
Sep 11, 2023
Sou Extension 2 Granted
Sep 13, 2023
Notice Of Approval Of Extension Request E-Mailed
Mar 6, 2024
Sou Teas Extension Received
Mar 6, 2024
Sou Extension 3 Granted
Mar 7, 2024
Notice Of Approval Of Extension Request E-Mailed
Sep 9, 2024
Sou Teas Extension Received
Sep 9, 2024
Notice Of Approval Of Extension Request E-Mailed
Sep 9, 2024
Sou Extension 4 Filed
Sep 9, 2024
Sou Extension 4 Granted

Trademark Alertz updated from USPTO on 2030-01-24